MDGL as reported
Madrigal Pharmaceuticals, Inc. reported $1.28B of revenue over the trailing twelve months, +149% on the year before. 9 reported series are charted on this page, each one as filed.
$1.28B
Revenue, trailing twelve months · to Q2 2026 · +149% against the twelve months before
- Net Income
- −$325M
Net Income · +15% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$207M
Free Cash Flow · −33% year on year · trailing twelve months to Q2 2026
- Op Margin
- −26%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.28B | +149% | Q2 2026 |
| Net Income | −$325M | +15% | Q2 2026 |
| EPS | −$13.98 | +20% | Q2 2026 |
| Op Margin | −26% | n/a | Q2 2026 |
| Net Margin | −26% | n/a | Q2 2026 |
| ROE | −53% | n/a | Q2 2026 |
| ROA | −24% | n/a | Q2 2026 |
| ROIC | −148% | n/a | Q2 2026 |
| Free Cash Flow | −$207M | −33% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Madrigal Pharmaceuticals, Inc. (MDGL) - Revenue & ProfitRevenue & ProfitMadrigal Pharmaceuticals, Inc. (MDGL)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com